MedTrace Logo

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

NCT02614872 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-09-01

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung transplantation.

Conditions

  • Transplantation, Lung Rejection

Interventions

DRUG

GLASSIA® and Institution standard of care (SOC)

Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)

Sponsors & Collaborators

  • Kamada, Ltd.

    lead INDUSTRY

Principal Investigators

  • Mordechai Kramer, MD · Pulmonary institute, Rabin Medical Center, Israel.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-26
Primary Completion
2019-04-11
Completion
2019-05-07

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614872 on ClinicalTrials.gov